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Abstract
There are over 400,000 out-of-hospital cardiac arrests (OHCA) in the United States annually. Of those, 50% are refractory
cardiac arrest, defined as the lack of return of spontaneous circulation (ROSC) after 30 minutes of appropriate cardiopulmonary
resuscitation (CPR) in the absence of hypothermia. Extracorporeal cardiopulmonary resuscitation (ECPR) has been increasingly
used given its potential to improve survival and offer improved neurological outcomes.
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use worldwide. Currently, ECPR is only offered in select,
pocketed locations in the United States.

Background
Out-of-hospital cardiac arrest (OHCA) carries a
significant socioeconomic burden to society. Following
OHCA, outcomes are favorable in patients younger than 75
years, with shockable rhythms (ventricular tachycardia or
fibrillation), and adequate cardiopulmonary resuscitation
(CPR) of less than 30 minutes. As the duration of CPR
increases, the survival and likelihood of a favorable
neurological outcome decreases dramatically, with very poor
outcomes after 30 minutes of CPR. In light of retrospective
data on OHCA and survival, extracorporeal cardiopulmonary
resuscitation (ECPR) has been recently recognized as a
potential approach to modulate this outcome and extend
favorable outcomes to 45 minutes for those in refractory
cardiac arrest [1].
For successful implementation of ECPR in OHCA, the
connection between emergency medical service and
extracorporeal membrane oxygenation (ECMO) teams, the
different disciplines, proper training, and operator familiarity
with performing ECPR are all critical elements. Japan, Korea
and, to a lesser extent, Taiwan have the highest rate of ECPR

Based out of Minneapolis, Minnesota, the ARREST trail
was led by Dr Yannopoulos et al.2 ARREST was the first USbased, randomized trial of ECPR. The study included adults
aged 18 to 75 years presenting to the University of Minnesota
Medical Center (MN, USA) with OHCA and refractory
ventricular fibrillation, no ROSC after three shocks,
automated CPR with a Lund University Cardiac Arrest
System (LUCAS), and an estimated transfer time shorter than
30 minutes. Patients were randomized on arrival to the
emergency room into one of two treatment arms: standard
advanced cardiovascular life support (ACLS) or early ECMOfacilitated CPR.2 A treatment algorithm for triage and
management after arrival to the emergency department was
used.
Survival to hospital discharge was observed in 1 (7%) of
15 patients (95% credible interval 1·6–30·2) in the standard
ACLS treatment group versus 6 (43%) of 14 patients (21·3–
67·7) in the early ECMO-facilitated resuscitation group. One
of the primary concerns of offering ECPR up front in OHCA
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is poor neurological outcomes with cerebral performance
category (CPC) scores of over 4. However, the ARREST trial
revealed that the neurological function was mainly preserved,
and functional status scores were significantly improved after
physical therapy and rehabilitation.2
It is important to consider complications of ECPR. ECPR
should not be viewed as a nothing to lose solution because
there are adverse events. Over time, ultrasound and
fluoroscopy have led to less complications: about 36% if not
used, compared to 8% when used.3 Limb ischemia was
between 3% to 15%, infection 8% to 20%, and bleeding at the
CPR site, insertion site, and abdominal bleeding were 28%,
49%, and 14%, respectively.
Based on the ARREST trial, the Minnesota Mobile
Resuscitation Consortium (MMRC) brought the ECPR to the
community. ECMO teams were deployed from an ECMO
center to regional facilities to perform ECPR quickly. Their
outcomes were surprisingly good, with 27 of 58 patients
(47%) surviving to hospital discharge and 25 of 58 with
favorable neurological outcome with a CPC score of 1 or 2.
The data further validates the ARREST trial results.
Belohlavek et al. randomized 256 patients in a single
center clinical trial in Prague, the Czech Republic, of adults
with witnessed OHCA of presumed cardiac origin without
ROSC to either an invasive strategy group of 124 patients
(mechanical compression, followed by intra-arrest transport to
a cardiac center for ECPR and immediate invasive assessment
and treatment) vs regular ACLS in the standard strategy
group.6 Thirty-nine patients (31.5%) in the invasive strategy
group and 29 (22.0%) in the standard strategy group survived
to 180 days with good neurologic outcomes (odds ratio [OR],
1.63 [95% CI, 0.93-2.85]; difference, 9.5% [95% CI, −1.3 to
20.1; P = .09). At 30 days, neurologic recovery had occurred
in 38 patients (30.6%) in the invasive strategy group and in 24
(18.2%) in the standard strategy group (OR, 1.99 [95% CI,
1.11-3.57]; difference, 12.4% [95% CI, 1.9-22.7]; P = .02),
and cardiac recovery had occurred in 54 (43.5%) and 45
(34.1%) patients, respectively (OR, 1.49 [95% CI, 0.91-2.47];
difference, 9.4% [95% CI, −2.5% to 21%]; P = .12). Bleeding
occurred more frequently in the invasive strategy vs standard
strategy group (31% vs 15%, respectively). Unlike the
ARREST trial, the bundle of early intra-arrest transport,
ECPR, and invasive assessment and treatment did not
significantly improve survival with neurologically favorable
outcome at 180 days compared with standard resuscitation.6
However, this study included shockable and nonshockable
rhythms; 64% of patients had an arrest of over 45 minutes;
LUCAS system was not used uniformly.
When combining data from the two clinical trials,
especially OHCA with shockable rhythms, there is a clear
mortality benefit from ECPR in OHCA.
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Ongoing Clinical Trials of ECPR
There are currently several ongoing ECPR trials
including EROCA, APACAR2, ECPB4OHCA, and
INCEPTION. The INCEPTION study is being done in the
Netherlands, where emergency medicine physicians follow a
different approach and are cannulating patients on ECMO.7
A recent meta-analysis of ECPR with hypothermia favors
therapeutic hypothermia with an odds ratio of survival of 2.27
(1.60, 3.23).5 Among 374 patients in the HYPO-ECMO
randomized clinical trial, which is a clinical trial of patients
who were eligible if they had been endotracheally intubated
and were receiving venoarterial ECMO for cardiogenic shock
for <6 hours. It was conducted in the intensive care units at 20
cardiac shock care centers in France between October 2016
and July 2019. Patients were randomized to either early
moderate hypothermia (33-34 °C; n = 168) for 24 hours or
strict normothermia (36-37 °C; n = 166). At 30 days, 71
patients (42%) in the moderate hypothermia group had died vs
84 patients (51%) in the normothermia group (adjusted odds
ratio, 0.71 [95% CI, 0.45-1.13], P = .15; risk difference,
−8.3% [95% CI, −16.3% to −0.3%]).8

Conclusion
All shock centers should consider implementing an ECPR
program and therapeutic hypothermia. ECPR improves
outcomes, and development of these programs is valuable in
managing refractory cardiac arrest, while also benefiting
patients in the timely implementation of ECMO, particularly
those with potentially reversible causes.
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